0000000000906638
AUTHOR
Carlos Alvarez
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
BACKGROUND: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated.METHODS: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population …
How the geometry of the scan body affects the accuracy of digital impressions in implant supported prosthesis. In vitro study
To determine and compare how three-dimensionally accurate scan bodies of different geometric shapes are placed over 6 implants (platform or crestal module). A master plaster model was made with 6 INHEX STD implant analogs made by Mozo-Grau S.A and 4 sca